Cergy

Researchers are evaluating treatment options for patients with lower limb peripheral arterial disease who have long lesions 15-25 cm in the superficial femoral artery causing intermittent claudication. This condition affects many active patients over age 60. The study aims to compare the effectiveness of femoro-popliteal bypass surgery versus endovascular procedures, as current evidence is limited and no dedicated clinical trial has directly compared these approaches. Participants will be randomly assigned to one of two groups. One group will receive a femoro-popliteal bypass under general or local anesthesia using the best available vascular substitute, such as an inverted saphenous vein or prosthesis. The other group will undergo an endovascular procedure involving balloon angioplasty, often followed by stent placement or drug-coated balloon angioplasty, performed under general anesthesia, local anesthesia, or sedation. During the study, participants will be monitored for up to two years. Researchers will assess the primary patency rate of the treated artery at 2 years, along with secondary patency rates at 1 and 2 years. Clinical improvements will be evaluated at several time points using the Rutherford classification and walking distance measures. Additional assessments include systolic pressure index, quality of life questionnaires, treatment burden, and adverse events like hematoma or infection. Participants will have regular follow-ups throughout the study period to track these outcomes.

Researchers are studying adults with bronchiectasis who have a recent infection of Pseudomonas aeruginosa PA in their airways. This infection is linked to more frequent worsening of symptoms, lower quality of life, and a higher risk of death. The study compares two antibiotic treatment plans to find out if a simpler oral and inhaled antibiotic combination works as well as a more intensive treatment involving intravenous antibiotics. This research aims to provide clearer evidence to guide how these infections should be treated for better health and economic outcomes. The study tests two treatment approaches over a 3-month period. One group receives an oral fluoroquinolone antibiotic combined with inhaled colistimethate sodium, starting with 14 days of both followed by 2.5 months of inhaled antibiotic alone. The other group gets intravenous beta-lactam antibiotic plus the same oral and inhaled antibiotics in the initial 14 days, then continues inhaled treatment alone for 2.5 months. After treatment, participants are followed for 9 more months to monitor their health and infection status, totaling 12 months from the start of therapy. Participants will have regular check-ups during and after treatment to measure how well PA is eradicated and to track any return of infection or worsening symptoms. Questionnaires will assess quality of life and treatment burden at the start, 3 months, and 12 months. Researchers will also monitor antibiotic resistance, adverse events, and healthcare costs over one year. This comprehensive follow-up helps evaluate both the medical and economic impact of the two antibiotic regimens in managing early PA airway infection in bronchiectasis.

This research aims to evaluate the functional and aesthetic outcomes of lower lip reconstructions, focusing on patient experiences as well as assessments by plastic surgeons and dermatologists. The study addresses the challenges of reconstructing lip tissue lost due to causes like cancer resection, trauma, infectious diseases, or congenital conditions. It highlights the importance of the lip for speech, eating, and facial expression, and the need to optimize therapeutic strategies to improve quality of life after reconstruction. The study observes patients who underwent various surgical reconstruction techniques for lower lip tissue loss, including locoregional flaps and free tissue transfers depending on the extent of tissue loss. Techniques like the Abbe, Estlander, Gilles, Bernard-Webster, and Karapandzic flaps are mentioned, with specific considerations for preserving muscle function and aesthetics. Reconstruction surgeries were performed as part of routine clinical care between January 2014 and October 2025. Participants complete self-reported questionnaires 12 months after surgery to assess their satisfaction with functional and aesthetic results, quality of life, and complications after reconstruction. The study also compares patient perceptions with professional assessments and examines correlations between surgical complexity and outcomes. Data collection involves postoperative follow-up consultations and patient-reported outcomes to help improve future treatment approaches.

Researchers are evaluating home treatment compared to hospitalisation for patients with active cancer and either symptomatic or incidental pulmonary embolism PE who do not meet the HESTIA criteria. This study aims to show that treating these patients at home is not worse than hospital care regarding a combined measure of recurrent blood clots, bleeding events, and death within 14 days. The trial also looks at patient quality of life, treatment satisfaction, and healthcare costs to find the best approach for managing cancer-associated PE. Participants are randomly assigned to one of two groups. Those in the home-treatment group will be discharged within 24 hours after randomisation and receive phone follow-up within 7 days from the local thrombosis team. Those in the hospitalisation group will stay in the hospital for at least 48 hours after randomisation, after which doctors may discharge them. Anticoagulant treatment will be started promptly in both groups according to local protocols, and patients are advised to report any new symptoms or bleeding. Throughout the study, participants will be followed up at 7, 14, 30, and 90 days to monitor clinical events such as recurrent PE, bleeding, or death. Patient-reported outcomes including quality of life and treatment satisfaction will be collected using questionnaires. Data on healthcare resource use and costs will also be gathered. An independent committee blinded to treatment groups will evaluate all clinical endpoints to ensure unbiased assessment of safety and effectiveness.

This research aims to evaluate in adult patients who require emergency tracheal intubation due to vital distress the effect of a combined strategy designed to reduce complications related to intubation. The study assesses how using rocuronium as a paralytic agent, providing bag face-mask ventilation before intubation, and systematically applying the Gum Elastic Bougie GEB at the first intubation attempt may impact intubation-related morbidity. Previous studies showed individual benefits of these approaches, but their combined effect in emergencies has not been assessed. The trial compares two groups one group receives a combination rapid sequence intubation RSI strategy using rocuronium, bag-mask ventilation between induction and laryngoscopy, and systematic GEB use to aid intubation. The other group follows current recommendations using succinylcholine for RSI, no routine bag-mask ventilation before intubation, and GEB use only if intubation fails under direct laryngoscopy. Emergency physicians perform intubations and record outcomes. Participants will be monitored closely during and after intubation. Data collection includes medical history, vital signs such as arterial pressure, oxygen saturation, and heart rate. Researchers will track severe intubation-related complications occurring within the first hour and assess intubation difficulty using various measures on the day of intubation. Outcomes like mortality and use of sedatives or vasopressors are recorded up to 28 days after inclusion. The overall study period extends until September 2026.

Researchers are comparing two treatments, rituximab and ocrelizumab, for patients with relapsing-remitting multiple sclerosis RRMS who have active disease. The study aims to show that rituximab is not inferior to ocrelizumab in the percentage of patients without disease activity after 2 years. This trial addresses the high cost differences between the treatments and the need to understand their relative effectiveness and safety in RRMS management. Participants receive either rituximab or ocrelizumab through infusions following a specific schedule rituximab is given as 300 mg on Day 0 and Day 15, then every 6 months ocrelizumab is given as 1000 mg on Day 0 and Day 15, then 500 mg every 6 months, up to 24 months. The study includes six follow-up visits over 2 years, aligned with routine treatment infusion times, and collects information on health status and quality of life. During the trial, participants complete health and quality of life questionnaires, and undergo clinical and MRI assessments to monitor disease activity and progression. Researchers measure outcomes like relapse rates, disability progression, MRI lesions, quality of life scores, and safety events. The study lasts 2 years, with visits planned at treatment initiation, 15 days later, and every 6 months thereafter to closely track participants health and treatment effects.

This trial studies adults aged 18 to 60 with Acute Myeloid Leukemia AML to improve overall survival using risk-adapted treatment strategies. It is an open-label, multicenter phase IIIII study evaluating different chemotherapy regimens during induction, consolidation, and, when applicable, stem cell transplantation. The study also assesses graft versus host disease GvHD prevention methods after transplant in intermediate-risk patients. Participants receive one of several chemotherapy induction regimens comparing daunorubicin and high-dose idarubicin combined with cytarabine. Consolidation treatment compares high-dose versus intermediate-dose cytarabine, sometimes combined with drugs like vosaroxin, dexamethasone, or venetoclax. For patients receiving allogeneic stem cell transplant, GvHD prophylaxis is studied comparing standard treatments such as methotrexate and cyclosporine with mycophenolic acid combinations. Treatment cycles and doses vary based on the patients risk and response. Throughout the study, participants undergo bone marrow evaluations, blood tests, and heart function assessments to monitor response and safety. Researchers track overall survival over three years, incidence of acute GvHD within 100 days post-transplant, and disease-free survival at 18 months. Participants provide informed consent and are monitored regularly during treatment and follow-up periods. The study completion is planned for January 2032.

Researchers are studying the effects of acetylsalicylic acid and atorvastatin on overall survival in patients with castrate-resistant prostate cancer CRPC who are starting first-line treatment. This international, open, phase III trial uses a 2x2 factorial randomized design to evaluate these drugs in addition to the standard care for CRPC. The study aims to understand whether adding these medications can improve survival outcomes for this patient group. Participants are randomly assigned to one of four groups standard of care alone, standard of care plus acetylsalicylic acid 100 mg daily, standard of care plus atorvastatin 80 mg daily, or standard of care plus both acetylsalicylic acid and atorvastatin. These treatments are taken daily alongside the usual care for their cancer. The trial monitors patients over up to 15 years to assess the long-term impact on survival. During the study, participants will be regularly evaluated for overall survival, which is calculated from the date of randomization until death. Researchers will also monitor patients for safety and adherence to the treatments. The trial includes detailed eligibility screening, performance status assessments, and laboratory tests to ensure patients meet the criteria to participate safely. The long follow-up period allows for comprehensive observation of treatment effects and patient outcomes.